Disease responses according to treatment group
| Treatment . | CR, n (%) . | VGPR* . | PR . | Stable . | PD . | Insufficient data . |
|---|---|---|---|---|---|---|
| 166Ho-DOTMP + Mel 140 | 3 (19) | 0 | 2 | 9 | 1 | 1 |
| 166Ho-DOTMP + Mel 140 + TBI | 10 (40) | 1 | 8 | 3 | 0 | 3 |
| 166Ho-DOTMP + Mel 200 | 16 (39) | 6 | 7 | 10 | 1 | 1 |
| Total, n (%) | 29 (35) | 7 (9) | 17 (21) | 22 (27) | 2 (2) | 5 (6) |
| Treatment . | CR, n (%) . | VGPR* . | PR . | Stable . | PD . | Insufficient data . |
|---|---|---|---|---|---|---|
| 166Ho-DOTMP + Mel 140 | 3 (19) | 0 | 2 | 9 | 1 | 1 |
| 166Ho-DOTMP + Mel 140 + TBI | 10 (40) | 1 | 8 | 3 | 0 | 3 |
| 166Ho-DOTMP + Mel 200 | 16 (39) | 6 | 7 | 10 | 1 | 1 |
| Total, n (%) | 29 (35) | 7 (9) | 17 (21) | 22 (27) | 2 (2) | 5 (6) |
Patient populations: 166Ho-DOTMP + Mel 140, n = 16; 166Ho-DOTMP + Mel 140 + TBI, n = 25; 166Ho-DOTMP + Mel 200, n = 41; and total, n = 82. PR indicates partial remission; VGPR, very good partial remission; and PD, progressive disease.
As defined by Attal et al.8